Plain-English translation of NCT07709780 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a newer blood-thinning medication, works as well as —the traditional treatment—for dissolving blood clots in the heart's left ventricle. Both medications prevent dangerous complications like stroke. The study will follow patients for a year to compare how well each one dissolves the clot and whether one is safer or easier to use than the other.
has been used for decades to treat heart blood clots, but it requires frequent blood tests and can be affected by food and other medications. This medication may offer a simpler alternative with fixed dosing and no routine monitoring needed, but doctors need solid evidence from a rigorous trial to confirm it works just as well.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either or by mouth. If assigned to , you'll need regular blood tests to monitor your treatment; if assigned to , you'll take a fixed dose with no routine monitoring. You'll have cardiac imaging (heart scans) at the start and at three months to see if the clot has dissolved, and you'll be followed for a full year to check for any complications, bleeding, or other heart-related events.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States